Cargando…
Releasing the brakes: a case report of pulmonary arterial hypertension induced by immune checkpoint inhibitor therapy
Immune checkpoint inhibitors successfully treat various malignancies by inducing an immune response to tumor cells. However, their use has been associated with a variety of autoimmune disorders, such as diabetes, hepatitis, and pneumonitis. Pulmonary arterial hypertension due to checkpoint inhibitor...
Autores principales: | Glick, Matthew, Baxter, Chase, Lopez, David, Mufti, Kashif, Sawada, Stephen, Lahm, Tim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675877/ https://www.ncbi.nlm.nih.gov/pubmed/33240485 http://dx.doi.org/10.1177/2045894020960967 |
Ejemplares similares
-
Riding the Ferrous Wheel of Iron Supplementation in Pulmonary Arterial Hypertension
por: Krasinkiewicz, Jonathan M., et al.
Publicado: (2021) -
Hungry for Chloride: Reprogramming Endothelial Cell Metabolism in Pulmonary Arterial Hypertension
por: Bousseau, Simon, et al.
Publicado: (2022) -
At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2020) -
Neurological complications of immune checkpoint inhibitors: what happens when you ‘take the brakes off’ the immune system
por: Dalakas, Marinos C.
Publicado: (2018) -
Identification of ACKR4 as an immune checkpoint in pulmonary arterial hypertension
por: Jiang, Chen-Yu, et al.
Publicado: (2023)